Read short summaries of the latest research literature published by Oncotarget.
Oncotarget’s Volume 12, Issue #5
Cover (Research Paper): The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy
Origin: New York, Vermont, South Carolina, United States; São Paulo, Brazil
Institutions: Northwell Health, Memorial Sloan-Kettering, Columbia University, University of Vermont Medical Center, City University of New York at Lehman College, Roper St. Francis Physician Partners Surgical Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Orygen Biotecnologia S.A.
Quote: “The aim of this study is to evaluate the CABYR isoforms: a/b and c mRNA expression in colorectal cancer (CRC) and to determine if these proteins hold promise as vaccine targets.”
Research Perspective: Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Origin: Massachusetts, United States
Institution: Brigham and Women’s Hospital, Dana-Farber Cancer Institute
Quote: “Tumor mutational burden (TMB) is a promising tool to help define patients with triple-negative breast cancer (TNBC) most likely to benefit from immune checkpoint blockade (ICB) therapies.”
Origin: Texas, United States; Tel Aviv, Israel
Institution: The University of Texas MD Anderson Cancer Center, Tel Aviv University
Quote: “The glioma associated oncogene-1 (GLI1), a downstream effector of the embryonic Hedgehog pathway, was detected in chronic lymphocytic leukemia (CLL), but not normal adult cells. GLI1 activating mutations were identified in 10% of patients with CLL. However, what induces GLI1 expression in GLI1-unmutated CLL cells is unknown.”
Research Paper: Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology
Origin: Utrecht, The Netherlands
Institutions: InteRNA Technologies BV
Quote: “Compelling evidence demonstrates that miR-193a-3p is a tumor suppressor microRNA in many cancer types, and its reduced expression is linked to cancer initiation and progression, metastasis, and therapy resistance. However, its mechanism of action is not consistently described between studies, and often contradicts the pleiotropic role of a microRNA in manipulating several different mRNA targets.”
Research Paper: Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity
Origin: Barcelona, Spain; United States
Institution: Universitat de Barcelona
Quote: “Dermatological adverse events (DAE) in hepatocellular carcinoma (HCC) patients treated with sorafenib predicts better outcome. Some turn into skin lesions (SL) requiring pathology examination. We describe incidence, characteristics and molecular profile of SL in HCC patients treated with sorafenib.”
Origin: Dresden, Leipzig, Germany; Budapest, Hungary
Institution: Institute of Radiopharmaceutical Cancer Research, Technische Universität Dresden, Semmelweis University, Universität Leipzig
Quote: “Here, we report on the in vitro and preclinical in vivo suitability of selected NODAGA-Ghrelin receptor inverse agonists as radiotracers. Rats and mice were used as standard radiopharmacological models with respect to biodistribution, metabolic stability and PET imaging assays.”
Research Paper: Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry
Origin: Paris, Rennes, Toulouse, France; Lima, Peru
Institution: Sorbonne Université, Institut Pasteur, Université de Rennes 1, Université de Toulouse, Instituto Nacional de Enfermedades Neoplásicas
Quote: “Here, we conducted an integrative analysis of gene expression and DNA methylation in HCC developed by patients from Peru. We report an original model of DNA hypermethylation associated with a gene expression signature that does not conform with the current molecular classification of HCCs.”
Research Paper: Fine–mapping of two differentiated thyroid carcinoma susceptibility loci at 2q35 and 8p12 in Europeans, Melanesians and Polynesians
Origin: Caen, Evry, Lyon, Nancy, Paris, Reims, Villejuif, France; Papeete, French Polynesia; La Havana, Cuba
Institution: University Paris-Saclay, Sorbonne Université, PSL University, Territorial Hospital Taaone, University of Lorraine, Université Paris Descartes, Université Paris Diderot, Centre François Baclesse, Inserm U1086 -UCN “ANTICIPE,” Institut Godinot, Institute of Oncology and Radiobiology, International Agency for Research on Cancer
Quote: “Here we performed fine-mapping of the 2q35 and 8p12 loci in the population of the EPITHYR consortium that includes Europeans, Melanesians and Polynesians to identify likely causal variants for DTC risk. We conducted a colocalization analysis using eQTLs data to determine the SNPs with the highest probability of causality.”
Origin: Bangalore, Karnataka, Kerala, Telangana, Secunderabad, India
Institution: CSIR-Centre for Cellular and Molecular Biology, Institute of Bioinformatics, Gandhi Hospital, Government Medical College, Manipal Academy of Higher Education
Quote: “Breast fibroepithelial lesions (FELs) include heterogeneous pathological tumors, involving indolent fibroadenoma (FAD) to potentially aggressive phyllodes tumors (PTs). The current grading system remains unreliable in differentiating these tumors due to histological heterogeneity and lack of appropriate markers to monitor the sudden and unpredictable malignant transformation of PTs. Thus, there exists an imminent need for a marker-based diagnostic approach to augment the conventional histological platform that could lead to accurate diagnosis and distinction of FELs.”
Click here to read Oncotarget’s Volume 12, Issue #5.
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact firstname.lastname@example.org.